<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3881">
  <stage>Registered</stage>
  <submitdate>12/03/2013</submitdate>
  <approvaldate>12/03/2013</approvaldate>
  <nctid>NCT01809665</nctid>
  <trial_identification>
    <studytitle>ProMRI PROVEN Master Study</studytitle>
    <scientifictitle>Master Study for the MRI Compatibility of the Solia S and Solia T Pacing Lead, the Linoxsmart ProMRI and Linoxsmart ProMRI DF4 ICD (Implantable Cardioverter-defibrillator) Lead and the Corox ProMRI OTW Coronary Sinus Lead in Combination With the Ilesto/Iforia ICD or the Evia/Entovis Triple Chamber Pacemaker</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>61</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Safety of MR (Magnetic Resonance) Conditional CRT-pacemakers and ICDs</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - ICD/CRT-P therapy
Other interventions - MRI

ICD/CRT-P therapy - Standard indication for ICD or triple-chamber pacemaker therapy


Treatment: devices: ICD/CRT-P therapy


Other interventions: MRI


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The Serious Adverse Device Effect (SADE) -free rate of the ICD/CRT-P system related to MRI</outcome>
      <timepoint>pre-MRI: approx. 2 to 5 months after implantation; post-MRI: 1 month (-2/+4 weeks) after MRI</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Increase in atrial and ventricular pacing threshold(s) between pre-MRI and 1-month post-MRI</outcome>
      <timepoint>pre-MRI: approx. 2 to 5 months after implantation; post-MRI: 1 month (-2/+4 weeks) after MRI</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Decrease in P-wave and R-wave amplitude (right and left) between pre-MRI and 1-month post-MRI.</outcome>
      <timepoint>pre-MRI: approx. 2 to 5 months after implantation; post-MRI: 1 month (-2/+4 weeks) after MRI</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent

          -  Able and willing to complete MRI testing

          -  Able and willing to activate and use the Cardio Messenger

          -  Able and willing to complete all testing required by the clinical protocol

          -  Available for all follow-up visits at the investigational site

          -  Standard indication for single, dual, or triple chamber ICD or CRT-P.

          -  ICD or CRT-P system to be implanted in the pectoral region

          -  Patient body height = 140 cm

          -  Age = 18 years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Standard contraindication for single, dual, or triple chamber ICD or CRT-P.

          -  Systems with an atrial lead: The patient has persistent (lasting longer than 7 days or
             requiring cardioversion) or permanent atrial arrhythmia

          -  Patient has other medical implants that may interact with MRI, e.g. abandoned
             pacemaker/ICD leads, lead extensions, mechanical valves, other active medical devices,
             non-MRI compatible devices

          -  Patient has other metallic artifacts / components in body that may interact with MRI

          -  Life expectancy of less than eight months

          -  Cardiac surgery in the next eight months

          -  Pregnant or breastfeeding

          -  Enrolled in another non-observational cardiac clinical investigation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>174</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Flinders Medical Center - Bedford Park</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>Royal North Shore Hospital - Sydney</hospital>
    <postcode> - Camperdown</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Sydney</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>St. Poelten</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Edmonton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Brest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Coburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Villingen Schwenningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Würzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Zürich</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biotronik SE &amp; Co. KG</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This investigation is designed to provide supporting evidence for the clinical safety of the
      Ilesto/Iforia ICD (implantable cardioverter-defibrillator)system and the Evia/Entovis HF-T
      (Heart Failure) triple chamber pacemaker system when used under specific MRI (magnetic
      resonance imaging) conditions.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01809665</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Wolfgang R. Bauer, Prof.Dr.Dr.</name>
      <address>Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik I, Oberdürrbacher Str. 6, 97080 Würzburg, Germany</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>